Maximus, Inc. (NYSE:MMS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “

MMS has been the subject of several other research reports. BidaskClub downgraded Maximus from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Maxim Group set a $66.00 price objective on Maximus and gave the company a “hold” rating in a research note on Thursday, August 3rd. Robert W. Baird restated a “hold” rating and set a $64.00 price objective on shares of Maximus in a research note on Friday, September 1st. Finally, Canaccord Genuity cut their price objective on Maximus from $62.00 to $61.00 and set a “hold” rating on the stock in a research note on Friday, November 10th. Two research analysts have rated the stock with a sell rating and six have issued a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $64.33.

Maximus (NYSE:MMS) traded down $0.47 during mid-day trading on Tuesday, reaching $64.31. The company’s stock had a trading volume of 212,200 shares, compared to its average volume of 362,426. Maximus has a 1 year low of $51.74 and a 1 year high of $66.96. The stock has a market capitalization of $4,199.18, a P/E ratio of 20.83, a PEG ratio of 2.42 and a beta of 1.32.

WARNING: “Maximus, Inc. (MMS) Stock Rating Lowered by Zacks Investment Research” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://theolympiareport.com/2017/11/16/maximus-inc-mms-stock-rating-lowered-by-zacks-investment-research.html.

In other Maximus news, Director Raymond B. Ruddy sold 25,000 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $62.68, for a total transaction of $1,567,000.00. Following the completion of the transaction, the director now directly owns 227,552 shares of the company’s stock, valued at approximately $14,262,959.36. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel David Francis sold 3,900 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $63.97, for a total value of $249,483.00. Following the transaction, the general counsel now directly owns 15,090 shares of the company’s stock, valued at $965,307.30. The disclosure for this sale can be found here. Insiders sold a total of 74,900 shares of company stock valued at $4,746,183 over the last three months. Corporate insiders own 3.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of MMS. Acrospire Investment Management LLC boosted its stake in Maximus by 17.6% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,000 shares of the health services provider’s stock valued at $125,000 after purchasing an additional 300 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Maximus by 10.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,367 shares of the health services provider’s stock valued at $148,000 after acquiring an additional 220 shares during the last quarter. First Bank & Trust lifted its position in shares of Maximus by 4.2% during the 2nd quarter. First Bank & Trust now owns 2,507 shares of the health services provider’s stock valued at $157,000 after acquiring an additional 101 shares during the last quarter. Intl Fcstone Inc. acquired a new stake in shares of Maximus during the 2nd quarter valued at $201,000. Finally, GW Henssler & Associates Ltd. acquired a new stake in shares of Maximus during the 2nd quarter valued at $205,000. 97.55% of the stock is owned by hedge funds and other institutional investors.

Maximus Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Analyst Recommendations for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.